原発性骨髄線維症（MF）、真性多血症後骨髄線維症（Post-PV MF）または本態性血小板血症後骨髄線維症（Post ET MF）患者を対象としたINC424のアジアにおける第II相臨床試験

基本情報

NCT ID

NCT01392443

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

120

治験依頼者名

Novartis

概要

The objective of this study was to determine the efficacy of INC424 as assessed by reduction in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF. The safety and tolerability of INC424 and the effects of INC424 on patient reported outcomes and the duration of response as assessed by reduction in spleen volume was also assessed.

対象疾患

介入

依頼者（Sponsor）